Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:41:32.699Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:41:32.699Z.
Quote observation: 2026-10-06T14:30:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4cebeea1a9b4d788b134268ad244658713bcf5e38577c227b803d15950d20ec6
FORWARD PE RATIO
N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.90M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.90M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.87M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.99M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.66M | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.21M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.55M | N/A |
| Femasys Inc. (FEMY)vs › | $6.28M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.55M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
Consensus estimates for this stock are reported in SGD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
